We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emergent BioSolutions (EBS) in Focus: Stock Rises 18.9%
Read MoreHide Full Article
Emergent BioSolutions Inc. (EBS - Free Report) was a big mover last session, as its shares rose almost 19% on the day. The move came after the company announced a new contract with the Centers for Disease Control and Prevention (CDC) and a separate deal with the Biomedical Advanced Research and Development Authority (BARDA), both to supply its anthrax vaccine BioThrax to the Strategic National Stockpile. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $26.27 to $31.40 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Emergent BioSolutions carries a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.
Is EBS going up? Or down? Predict to see what others think: Up or Down
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Emergent BioSolutions (EBS) in Focus: Stock Rises 18.9%
Emergent BioSolutions Inc. (EBS - Free Report) was a big mover last session, as its shares rose almost 19% on the day. The move came after the company announced a new contract with the Centers for Disease Control and Prevention (CDC) and a separate deal with the Biomedical Advanced Research and Development Authority (BARDA), both to supply its anthrax vaccine BioThrax to the Strategic National Stockpile. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $26.27 to $31.40 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Emergent BioSolutions carries a Zacks Rank #5 (Strong Sell) while its Earnings ESP is 0.00%.
EMERGENT BIOSOL Price
EMERGENT BIOSOL Price | EMERGENT BIOSOL Quote
A better-ranked stock in the medical-biomedical and genetics space is Athersys, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is EBS going up? Or down? Predict to see what others think: Up or Down
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>